iBio Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Subsequent Events (Narrative) (Details)

Subsequent Events (Narrative) (Details)											12 Months Ended
Subsequent Events (Narrative) (Details)	Sep. 23, 2021 USD ($) $ / shares shares	Sep. 11, 2021 ft² $ / ft²	Aug. 23, 2021 USD ($) $ / shares shares	Jul. 19, 2021 $ / shares shares	Jul. 12, 2021 $ / shares shares	May 04, 2021 USD ($) $ / shares	Jan. 18, 2021 USD ($) $ / shares	Sep. 11, 2020 USD ($)	Jun. 20, 2020	Mar. 27, 2020 USD ($) $ / shares	Jun. 30, 2021 $ / shares shares	Jun. 30, 2020 shares
Subsequent Event [Line Items]
Number of options granted \| shares											5,240,000	2,383,300
Weighted-average exercise price per share \| $ / shares											$ 1.44
Vesting period									2 years
Share based payment plan term									10 years
Planet Biotechnologies [Member]
Subsequent Event [Line Items]
One-time up-front payment								$ 150,000
Subsequent Event [Member] \| RubrYc Theraputics, Inc. [Member] \| Event of Non-Payment [Member] \| Novel Antibody Therapeutics [Member]
Subsequent Event [Line Items]
Collaboration and license agreement, period to cure breach of contract			30 days
Subsequent Event [Member] \| RubrYc Theraputics, Inc. [Member] \| Clinical Development and Regulatory Milestone Payments [Member] \| Immune-Oncology Antibodies (RTX-003) [Member]
Subsequent Event [Line Items]
Milestone payments			$ 15,000,000
Subsequent Event [Member] \| RubrYc Theraputics, Inc. [Member] \| Clinical Development and Regulatory Milestone Payments [Member] \| Novel Antibody Therapeutics [Member]
Subsequent Event [Line Items]
Milestone payments			$ 15,000,000
Subsequent Event [Member] \| SAN DIEGO INSPIRE 4, LLC [Member]
Subsequent Event [Line Items]
Area of lab and office \| ft²		11,383
Operating lease, term of contract		7 years
operating lease, base rent rate per month \| $ / ft²		4.50
Annual percentage increase in base rent		3.00%
Subsequent Event [Member] \| Collaboration, Option and License Agreement [Member] \| RubrYc Theraputics, Inc. [Member] \| Immune-Oncology Antibodies (RTX-003) [Member]
Subsequent Event [Line Items]
Collaboration and license agreement, royalty payment term			10 years
Collaboration and license agreement, period to cure breach of contract			60 days
Collaboration and license agreement, notice duration to terminate contract			90 days
Subsequent Event [Member] \| Collaboration, Option and License Agreement [Member] \| RubrYc Theraputics, Inc. [Member] \| Novel Antibody Therapeutics [Member]
Subsequent Event [Line Items]
Collaboration and license agreement, royalty payment term			10 years
Collaboration and license agreement, period to cure breach of contract			60 days
Collaboration and license agreement, agreement term			5 years
Collaboration and license agreement, notice duration to terminate contract			90 days
Subsequent Event [Member] \| Collaboration, Option and License Agreement [Member] \| RubrYc Theraputics, Inc. [Member] \| Event of Non-Payment [Member] \| Immune-Oncology Antibodies (RTX-003) [Member]
Subsequent Event [Line Items]
Collaboration and license agreement, period to cure breach of contract			30 days
Subsequent Event [Member] \| Collaboration, Option and License Agreement [Member] \| RubrYc Theraputics, Inc. [Member] \| Event of Non-Payment [Member] \| Novel Antibody Therapeutics [Member]
Subsequent Event [Line Items]
Collaboration and license agreement, period to cure breach of contract			30 days
Subsequent Event [Member] \| Collaboration, Option and License Agreement [Member] \| RubrYc Theraputics, Inc. [Member] \| Financing Requirement not Met [Member] \| Immune-Oncology Antibodies (RTX-003) [Member]
Subsequent Event [Line Items]
Collaboration and license agreement, notice duration to terminate contract			30 days
Subsequent Event [Member] \| Series A-2 Preferred Stock [Member] \| Stock Purchase Agreement [Member] \| RubrYc Theraputics, Inc. [Member] \| Immune-Oncology Antibodies (RTX-003) [Member]
Subsequent Event [Line Items]
Stock purchase agreement, number of shares purchased \| shares			1,909,563
Stock purchase agreement, value of shares purchased			$ 5,000,000
Stock purchase agreement, number of shares to be purchased \| shares			954,782
Stock purchase agreement, value of shares to be purchased			$ 2,500,000
Preferential dividend rate percentage			8.00%
Minimum required shares to be eligible for preferential dividend rate \| shares			1,500,000
Proceeds from conversion of preferred stock to common stock			$ 30,000,000
Stock Options [Member] \| Subsequent Event [Member] \| Chief Executive Officer [Member]
Subsequent Event [Line Items]
Number of options granted \| shares	2,000,000
Weighted-average exercise price per share \| $ / shares	$ 1.17
Vesting period	36 months
Officer's compensation, bonus	$ 509,000
Stock Options [Member] \| Subsequent Event [Member] \| Directors [Member]
Subsequent Event [Line Items]
Number of options granted \| shares			100,000
Weighted-average exercise price per share \| $ / shares			$ 1.26
Vesting period			3 years
Share based payment plan term			10 years
Stock Options [Member] \| Subsequent Event [Member] \| Employees [Member]
Subsequent Event [Line Items]
Number of options granted \| shares			3,937,191	25,000	25,000
Weighted-average exercise price per share \| $ / shares			$ 1.26	$ 1.41	$ 1.35
Vesting period			3 years	3 years	3 years
Share based payment plan term			10 years	10 years	10 years
Restricted Stock Units [Member]
Subsequent Event [Line Items]
Vesting period						4 years
Share-based award, market value per share \| $ / shares						$ 1.29
Share based payment award, Grant-date fair value						$ 52,000
Restricted Stock Units [Member] \| Employees [Member]
Subsequent Event [Line Items]
Vesting period							3 years			4 years
Share-based award, market value per share \| $ / shares							$ 1.47			$ 1.15
Share based payment award, Grant-date fair value							$ 96,000			$ 47,000
Restricted Stock Units [Member] \| Subsequent Event [Member] \| Employees [Member]
Subsequent Event [Line Items]
Vesting period			4 years
Share-based award, Number of awards issued \| shares			105,723
Share-based award, market value per share \| $ / shares			$ 1.26
Share based payment award, Grant-date fair value			$ 133,000